Applicant, as named in the Orange Book

Avyxa Holdings

Next listed expiry: Frindovyx on 1 Dec 2035. 5 products with live protection, 6 without.

Products with listed protection

Drug	Ingredient	NDA	Earliest generic entry	Basis
Frindovyx · 3 strengths cyclophosphamide	cyclophosphamide	210852	1 Dec 2035	patent
Docivyx · 3 strengths docetaxel	docetaxel	215813	14 Mar 2036	patent
Vykoura · 3 strengths leucovorin calcium	leucovorin calcium	220406	23 Dec 2044	patent
Kyxata · 2 strengths carboplatin	carboplatin	219921	1 Apr 2045	patent
Axtle · 2 strengths pemetrexed dipotassium	pemetrexed dipotassium	210661	25 Jun 2045	patent

No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.

Products without listed protection (6)

Drug	Ingredient	NDA	Earliest generic entry	Basis
Avgemsi · 2 strengths gemcitabine hydrochloride	gemcitabine hydrochloride	219920	open now	no listed protection
Avopef · 2 strengths etoposide	etoposide	220200	open now	no listed protection
Favlyxa · 2 strengths fluorouracil	fluorouracil	220201	open now	no listed protection
Gobarden bendamustine hydrochloride	bendamustine hydrochloride	219014	open now	no listed protection
Navitrux fosaprepitant dimeglumine	fosaprepitant dimeglumine	220436	open now	no listed protection
Posfrea palonosetron hydrochloride	palonosetron hydrochloride	203050	open now	no listed protection